Photo of Marc B. Garnick,  MD

Marc B. Garnick, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 735-2062
Fax: (617) 632-9260

Marc B. Garnick, MD

Beth Israel Deaconess Medical Center


  • Gorman Brothers Clinical Professor of Medicine, Medicine, Harvard Medical School
  • Gorman Brothers Professor of Medicine, Medicine, Beth Israel Deaconess Medical Center


Research Abstract

Marc B. Garnick, MD is an internationally renowned expert in medical oncology and urologic cancer at Beth Israel Deaconess Medical Center (BIDMC) and the Gorman Brothers Professor of Medicine at Harvard Medical School. He has dedicated his career to the development of new therapies for the treatment of prostate cancer. To advance research in prostate cancer, Dr. Garnick founded the Hershey Family Foundation for Prostate Cancer Research. He serves as Editor-in-Chief of Harvard Medical School’s Annual Report on Prostate Diseases and its website

In addition to his academic affiliations and clinical patient care, Dr. Garnick serves as Director of Community Cancer Services for Network Development at BIDMC and is the Executive Director of Physician Initiated Philanthropy at BIDMC. A sought after speaker Dr. Garnick serves as a special advisor to the FDA; medical advisor to World Book encyclopedia; a Vice Chair of the BIDMC Trustee Advisory Board and a member of the Foundation Committee, Member of the Penn Medicine Board, and Trustee Emeritus of Bowdoin College.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Garnick MB, Einstein DJ. EDITORIAL COMMENT. Urology 2019; 131:182-183. PubMed
  • Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, Eckel RH, Keane TE, Shore ND, Dahdal DN, Beveridge TJ, Marshall DC. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol 2017. PubMed
  • Garnick MB. Testosterone replacement therapy faces FDA scrutiny. JAMA 2015; 313:563-4. PubMed
  • Garnick MB. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study. J Clin Oncol 2013; 31:3746-8. PubMed
  • Garnick MB. Possible confusion in names of new treatments for prostate cancer. N Engl J Med 2013; 368:194. PubMed
  • San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011; 185:471-6. PubMed
  • Garnick MB. Editorial comment. Urology 2010; 75:1428-30; author reply 1430. PubMed
  • Garnick MB. Screening and detection of breast cancer and prostate cancer. JAMA 2010; 303:1033; author reply 1033-4. PubMed
  • Garnick MB. Important considerations in LHRH antagonist therapy for prostate cancer. Oncology (Huntingt) 2009; 23:636-7. PubMed
  • Garnick MB. Redefining the refined retroperitoneal lymph node dissection in testis cancer: a SWOT analysis of nonrandomized data. J Clin Oncol 2007; 25:4337-8. PubMed
  • Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2006; 2:677-96. PubMed
  • Beer TM, Ryan C, Bhat G, Garnick M,. Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study. Anticancer Drugs 2006; 17:1075-9. PubMed
  • Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176:520-5. PubMed